Vikas Sayal, MD
Pulmonary Disease · Bullhead City, AZNPI 1811109226
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,190 of the $84,942 with a category attached, or 76.7%. 43 manufacturers reported payments, led by GSK at 41.7% of the total. Reporting peaked in 2023 at $26,904 and has fallen 88.8% since, to $3,006 in 2025. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 819 payments — averaging $103.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$35K
- AstraZeneca$34K
- Sunovion Pharmaceuticals Inc.$2K
- Viiv Healthcare Company$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Electromed, Inc.$1K
- plus $9K from 37 others
Across 603 payments — averaging $5953.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$1.1M
- GSK$670K
- Sanofi US Services Inc.$413K
- Takeda Pharmaceuticals U.S.A., Inc.$408K
- AstraZeneca$305K
- Chiesi USA, Inc.$253K
- plus $473K from 9 others
What the payments were for
- Speaking & faculty fees$65,19077%
- Travel & lodging$1,1561%
- Food & beverage$18,18921%
- Education$4080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$30,557
- TRELEGY ELLIPTA$18,073
- LONHALA MAGNAIR$2,134
- FASENRA$1,038
- Da Vinci Surgical System$731
- BEVESPI AEROSPHERE$495
- FARXIGA$495
- BREZTRI AEROSPHERE$450
- TEZSPIRE$438
- AIRSUPRA$438
- SYMBICORT$269
- DUPIXENT$236
- NUCALA$231
- Enhertu$156
- ICEfx Cryoablation System$150
- FOUNDATIONONE$148
- FOUNDATIONONE HEME$148
- FOUNDATIONONE CDX$148
- FOUNDATIONFOCUS$148
- FOUNDATIONONE LIQUID CDX$148
How this compares
$84,942 in reported general payments places this provider in the 90th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 54 | $701,769 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 383 | $491,657 |
| Tyvaso DpiTreprostinil | 15 | $350,962 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 134 | $184,286 |
| Dupixent PenDupilumab | 23 | $115,348 |
| Spiriva RespimatTiotropium Bromide | 72 | $83,213 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $70,446 |
| TezspireTezepelumab-Ekko | 11 | $47,301 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 174 | $35,815 |
| Wixela InhubFluticasone Propion/Salmeterol | 215 | $35,032 |
| SymbicortBudesonide/Formoterol Fumarate | 85 | $32,549 |
| Arnuity ElliptaFluticasone Furoate | 20 | $10,980 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 356 | $9,195 |
| BreynaBudesonide/Formoterol Fumarate | 30 | $8,881 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $895 | $784,982126 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $35,414 | $588,199512 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $33,806 | $264,136230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Bullhead City
- George ParidesMesa$913K
- Rajat WaliaPhoenix$748K
- Abhinav MittalTucson$570K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Richard SueGilbert$224K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.